{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T16:08:33Z","timestamp":1648656513848},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T00:00:00Z","timestamp":1367452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00277-013-1771-8","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T03:14:45Z","timestamp":1367464485000},"page":"177-178","source":"Crossref","is-referenced-by-count":1,"title":["Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH)"],"prefix":"10.1007","volume":"93","author":[{"given":"Igor","family":"Aurer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Ba\u0161i\u0107-Kinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Radman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Ili\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josip Joachim","family":"Grah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,2]]},"reference":[{"key":"1771_CR1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569\u20131580","journal-title":"Cancer"},{"key":"1771_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","volume":"113","author":"A Oriol","year":"2008","unstructured":"Oriol A, Ribera JM, Bergua J, Gimenez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D (2008) High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 113:117\u2013125","journal-title":"Cancer"},{"issue":"suppl.4","key":"1771_CR3","first-page":"83","volume":"19","author":"D Hoelzer","year":"2008","unstructured":"Hoelzer D (2008) Recent results in the treatment of Burkitt lymphomas. Ann Oncol 19(suppl4):83, abstr.8","journal-title":"Ann Oncol"},{"key":"1771_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2008.07.024","volume":"33","author":"L Grisekvicius","year":"2009","unstructured":"Grisekvicius L, Stulpinas R, Saulyte-Trakymiene S, Mickys U, Pranys D, Kurtinaitis J, Jurgutis M (2009) Favorable outcome with chemo-immunotherapy in Burkitt lymphoma and leukemia. Leuk Res 33:587\u2013588","journal-title":"Leuk Res"},{"key":"1771_CR5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.V116.21.858.858","volume":"116","author":"DA Rizzieri","year":"2010","unstructured":"Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Powell BL, Shea TC, Nattom S, Hoke E, Cheson BD, Larson R (2010) Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia\/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002. Blood 116:374, abstr.858","journal-title":"Blood"},{"key":"1771_CR6","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","volume":"22","author":"JA Barnes","year":"2011","unstructured":"Barnes JA, LaCasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS (2011) Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol 22:1859\u20131864","journal-title":"Ann Oncol"},{"key":"1771_CR7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000334705","volume":"127","author":"D Dujmovic","year":"2012","unstructured":"Dujmovic D, Aurer I, Radman I, Serventi-Seiwerth R, Dotlic S, Stern-Padovan R, Dubravcic K, Santek F, Labar B (2012) Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma\/leukemia. Acta Haematol 127:115\u2013117","journal-title":"Acta Haematol"},{"issue":"suppl.4","key":"1771_CR8","first-page":"83","volume":"19","author":"K Dunleavy","year":"2008","unstructured":"Dunleavy K, Little RF, Pittaluga S, Grant N, Shovlin M, Steinberg S, Yarchoan R, Janik J, Jaffe ES, Wilson WH (2008) A prospective study of dose-adjusted (DA) EPOCH with rituximab in adults with newly diagnosed Burkitt lymphoma: a regimen with high efficacy and low toxicity. Ann Oncol 19(suppl4):83\u201384, abstr.9","journal-title":"Ann Oncol"},{"key":"1771_CR9","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","volume":"99","author":"WH Wilson","year":"2002","unstructured":"Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99:2685\u20132693","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1771-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1771-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T04:54:43Z","timestamp":1595739283000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1771-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,2]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["1771"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1771-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,2]]}}}